Osteopontin promotes the development of natural killer cells from hematopoietic stem cells

Stem Cells

Volumn 26, Issue 8, 2008, Pages 2114-2123

  Jin, Woong Chung ^a   Mi, Sun Kim ^a,c   Piao, Zheng Hao ^a   Jeong, Mira ^a   Suk, Ran Yoon ^a   Shin, Nara ^a   Sang, Yong Kim ^a   Eun, Sook Hwang ^b   Yang, Young ^c   Young, Ho Lee ^d   Young, Sang Kim ^c   Choi, Inpyo ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Ewha Womans University   (South Korea)

^c Sookmyung Women's University   (South Korea)

^d Chungnam National University   (South Korea)

Author keywords

Hematopoietic stem cells; Interleukin 15; Natural killer cells; Osteopontin

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR BETA; NATURAL KILLER CELL RECEPTOR; OSTEOPONTIN; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; BONE MARROW CELL; C57BL 6 MOUSE; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL POPULATION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; MICROENVIRONMENT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN; STROMA CELL; TRANSGENIC MOUSE;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; INTERLEUKIN-15; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; OSTEOPONTIN; RECOMBINANT PROTEINS; SPLEEN; T-BOX DOMAIN PROTEINS;

MUS;

EID: 55049136168     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0370     Document Type: Article

References (38)

1. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev 2006;214:56-72.
2. Di Santo JP. Natural killer cell developmental pathways: A question of balance. Annu Rev Immunol 2006;24:257-286.
3. van den Brink MR, Boggs SS, Herberman RB et al. The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures. J Exp Med 1990;172:303-313.
4. Ogasawara K, Hida S, Azimi N et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998;391:700-703.
5. Mrózek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996;87:2632-2640.
6. Williams NS, Klem J, Puzanov IJ et al. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. J Immunol 1999;163:2648-2656.
7. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000;11:279-303.
8. Takeshita S, Arai S, Kudo A. Identification and characterization of mouse bone marrow stromal cell lines immortalized by temperature-sensitive SV40 T antigen: Supportive activity for osteoclast differentiation. Bone 2001;29:236-241.
9. Leboy PS, Beresford JN, Devlin C et al. Dexamethasone induction of osteoblast mRNAs in rat marrow stromal cell cultures. J Cell Physiol 1991;146:370-378.
10. Benayahu D, Gurevitz OA, Shamay A. Bone-related matrix proteins expression in vitro and in vivo by marrow stromal cell line. Tissue Cell 1994;26:661-666.
11. Ashkar S, Weber GF, Panoutsakopoulou V et al. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000;287:860-864.
12. Iizuka J, Katagiri Y, Tada N et al. Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest J Tech Methods Pathol 1998;78:1523-1533.
13. Okamoto H. Osteopontin and cardiovascular system. Mol Cell Biochem 2007;300:1-7.
14. Weber GF, Cantor H. The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev 1996;7:241-248.
15. Renkl AC, Wussler J, Ahrens T et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 2005;106:946 -955.
16. Li X, O'Regan AW, Berman JS. IFN-gamma induction of osteopontin expression in human monocytoid cells. J Interferon Cytokine Res 2003;23:259-265.
17. Lee KM, McNerney ME, Stepp SE et al. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med 2004;199:1245-1254.
18. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985;162:1745-1759.
19. Rosmaraki EE, Douagi I, Roth C et al. Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol 2001;31:1900-1909.
20. Cheng SL, Zhang SF, Avioli LV. Expression of bone matrix proteins during dexamethasone-induced mineralization of human bone marrow stromal cells. J Cell Biochem 1996;61:182-193.
21. Shin H, Temenoff JS, Bowden GC et al. Osteogenic differentiation of rat bone marrow stromal cells cultured on Arg-Gly-Asp modified hydrogels without dexamethasone and beta-glycerol phosphate. Biomaterials 2005;26:3645-3654.
22. Johnson GA, Burghardt RC, Joyce MM et al. Osteopontin expression in uterine stroma indicates a decidualization-like differentiation during ovine pregnancy. Biol Reprod 2003;68:1951-1958.
23. Mingari MC, Vitale C, Cantoni C et al. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: Selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Eur J Immunol 1997;27:1374-1380.
24. Carson WE, Giri JG, Lindemann MJ et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395-1403.
25. Puzanov IJ, Bennett M, Kumar V. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J Immunol 1996;157:4282-4285.
26. Kang HS, Kim EM, Lee S et al. Stage-dependent gene expression profiles during natural killer cell development. Genomics 2005;86:551-565.
27. Szabo SJ, Sullivan BM, Stemmann C et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002;295:338-342.
28. Townsend MJ, Weinmann AS, Matsuda JL et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004;20:477-494.
29. Matsui M, Moriya O, Yoshimoto T et al. T-bet is required for protection against vaccinia virus infection. J Virol 2005;79:12798-12806.
30. Shinohara ML, Jansson M, Hwang ES et al. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci U S A 2005;102:17101-17106.
31. Shinohara ML, Lu L, Bu J et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 2006;7:498-506.
32. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006;25:455-471.
33. Intlekofer AM, Takemoto N, Wherry EJ et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005;6:1236-1244.
34. Beima KM, Miazgowicz MM, Lewis MD et al. T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects. J Biol Chem 2006;281:11992-12000.
35. Matsuda JL, George TC, Hagman J et al. Temporal dissection of T-bet functions. J Immunol 2007;178:3457-3465.
36. Nilsson SK, Johnston HM, Whitty GA et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005;106:1232-1239.
37. Stier S, Ko Y, Forkert R et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 2005;201:1781-1791.
38. Christensen B, Kazanecki CC, Petersen TE et al. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 2007;282:19463-19472.